Joint Formulary & PAD

Cariprazine - Schizophrenia and other psychoses

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Capsules
Associated Icons :
SPC
Restrictions / Comments :
Important

The specialist team will initiate and prescribe cariprazine for a minimum of 3 months, after monitoring for treatment efficacy has been completed and the patient has been stable (defined such that symptoms are not interfering with daily life) for at least 1 month

PAD Profile

ChemicalSubstance :
Cariprazine
Indication :
Schizophrenia and other psychoses
Group Name :
Keywords :
antipsychotics
Brand Names Include :
Reagila
Important Information :

Mental health specialists only.

Patient must be on highly effective contraceptive

Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1

Committee Recommendations (1)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed to change the traffic light status of cariprazine for the treatment of schizophrenia in adults.

Cariprazine for this indication will be given a BLUE (with specialist team initiation) traffic light status. Prescribing of cariprazine can be transferred to primary care after a minimum of 3 months, after monitoring for treatment efficacy has been completed by the specialist team and the patient has been stable (defined such that symptoms are not interfering with daily life) for at least 1 month.

Other Indications

Below are listed other indications that Cariprazine is used to treat.

  • No records returned.